Research menu
Jump to menu

Publications:  Dr Craig Stiles

Stiles CE, Steeds RP, Drake WM(2020). Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia. Ann Endocrinol (Paris)
Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP, Drake WM(2018). A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. J Clin Endocrinol Metab
Stiles CE, Thuraisingham R, Bockenhauer D, Platts L, Kumar AV, Korbonits M(2018). De novo HNF1 homeobox B mutation as a cause for chronic, treatment-resistant hypomagnesaemia. Endocrinol Diabetes Metab Case Rep vol. 2018,
Radian S, Diekmann Y, Gabrovska P, Holland B, Bradley L, Wallace H, Stals K, Bussell AM et al.(2017). Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland. Human Mutation vol. 38, (1) 78-85.
Drake WM, Stiles CE, Bevan JS, Karavitaki N, Trainer PJ, Rees DA, Richardson TI, Baldeweg SE et al.(2016). A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. J Clin Endocrinol Metab vol. 101, (11) 4189-4194.
Rodd C, Millette M, Iacovazzo D, Stiles CE, Barry S, Evanson J, Albrecht S, Caswell R et al.(2016). Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)—Diagnosis and Management. The Journal of Clinical Endocrinology & Metabolism vol. 101, (5) 1927-1930.
Dénes J, Kasuki L, Trivellin G, Colli LM, Takiya CM, Stiles CE, Barry S, De Castro M et al.(2015). Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas. PLoS ONE vol. 10, (2)
Radian S, Gabrovska P, Holland B, Wallace H, Ryan AW, McGurren K, Stals K, Bussell A-M et al. (2014). Population Screening for the Irish Founder AIP Mutation R304*Reveals a Prevalence of 1/500 in the Local Population, While High Mutation Frequency Is Present Among Irish Familial and Sporadic Somatotropinoma Patients. ENDOCRINE REVIEWS. vol. 35,
Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS, Steeds RP, UK Dopamine Agonist Valvulopathy Group(2014). A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab vol. 99, (1) 90-96.
Return to top